China: A large multinational study published in the BMJ journal Gut has revealed that individuals with lean metabolic dysfunction-associated steatotic liver disease (MASLD) —those with normal body weight —face significantly worse liver-related outcomes and higher mortality risks compared to their non-lean counterparts. The findings challenge the perception that MASLD is a condition primarily affecting those who are overweight or obese. The study, led by Dr. Zhenyu Huo and colleagues from the Department of Gastroenterology, Beijing Friendship Hospital, Capital Medical University, Beijing, China, analyzed long-term data from three major population-based cohorts: the UK Biobank, the Kailuan cohort, and the China Kadoorie Biobank. In total, data from 186,000 participants with MASLD w

See Full Page